A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
NCT07222670
This study is recruiting at 5 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Viral Respiratory Infection
- Viral Respiratory Illnesses
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- ENA Respiratory Pty Ltd
- Last updated on ClinicalTrials.gov
- September 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 2
- Center for Vaccine Development and Global Health (CVD) · Baltimore, MD
- Naval Medical Research Command (NMRC) · Bethesda, MD
North Carolina · 3
- Accellacare of Raleigh · Raleigh, NC
- Accellacare of Piedmont HealthCare · Statesville, NC
- Accellacare - Wilmington · Wilmington, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.